

ECCVID

ESCMID Conference on Coronavirus Disease

Emerging threats, emerging solutions 23 – 25 September 2020

CONFIRMED SESSIONS

Table of Content

nvited Speaker Sessions
Keynote Speakers3
Lectures
Interview Sessions
One-hour Symposia6
23 September 2020
24 September 2020
25 September 2020
One-hour Q&A 22
23 September 2020
24 September 2020
25 September 2020
Meet-the-Expert
Oral Sessions
Abstract Sessions
23 September 2020
24 September 2020
25 September 2020
Clinical Case Sessions
Practical Workshops



dustry Sessions	Ind
Virtual Industry Learnings	v
Virtual Integrated Symposia 55	v
AstraZeneca	
Seegene	
PFIZER	
MSD	
GILEAD	
Beckman Coulter Life Sciences 59	
GILEAD 59	







Please note: This is not the final programme. As sessions are confirmed, this document will be updated daily to give the most up-to-date information.

ECCVID

Keynote Speakers

	The multifaceted response to COVID-19 in the EU
Andrea Ammon Sweden	23 September 2020 - 10:45 – 11:15 CEST
	Chairs: Jacob Moran Gilad, Israel and Annelies Zinkernagel, Switzerland
	Modes of transmission of SARS-CoV-2: evidence and gaps
Marion Koopmans Netherlands	23 September 2020 - 11:30 – 12:00 CEST
	Chairs: Maurizio Sanguinetti, Italy and Mario Ramirez, Portugal
	COVID-19 vaccines: current state of play
Mark Mulligan USA	23 September 2020 - 16:00 – 16:30
	Chairs: Jon Friedland, UK and Pasi Pentinnen, Finland
	360 degrees around immunity conferred by SARS-CoV-2
Peter Simmonds United Kingdom	24 September 2020 - 10:15 – 10:45 CEST
	Chairs: Mary Horgan, Ireland and Thea K. Fischer, Denmark
	Use of convalescent plasma for COVID-19 treatment
Arturo Casadevall USA	24 September 2020 - 16:00 – 16:30 CEST
	Chairs: Margaret Ip, China and Alexandra Mailles, France
	SARS-CoV-2 outbreak management: the Vo' lesson
Andrea Crisanti Italy	24 September 2020 - 16:30 – 17:00 CEST
	Chairs: Yong-Zhen Zhang, China and Murat Akova, Turkey



Keynote Speakers

Luke O'Neill	Prospects for anti-inflammatory therapies for COVID-19
Ireland	25 September 2020 - 10:15 – 10:45 CEST
	Chairs: Souha Kanj, Lebanon and TBD
	Next steps in diagnostics for curing COVID-19
Maria Zambon United Kingdom	25 September 2020 - 10:45 – 11:15 CEST
	Chairs: Snjezana Zidovec Lepej, Croatia and Alex Friedrich, Netherlands
	Global response to COVID-19: next steps
Maria van Kherkove Switzerland	25 September 2020 - 15:30 – 16:00 CEST
	Chairs: David Heymann, UK and Jesús Rodriguez Baño, Spain
	News regarding COVID-19 vaccines
Andrew Pollard United Kingdom	25 September 2020 - 16:00 – 16:30 CEST
	Chairs: TBD
	Modelling a pandemic in real time:
Ashleigh Tuite	lessons learned from disease models for COVID-19
Canada	25 September 2020 - 16:30 – 17:00 CEST
	Chairs: Mirjam Kretzschmar, Netherlands and TBD
	Global mental health during the COVID-19 pandemic and beyond
Vikram Patel USA	25 September 2020 - 9:00 – 9:30 CEST
	Chairs: Eskild Petersen, Denmark and Emmanuelle Cambau, France



Keynote Speakers

Interview Sessions:

These Keynote sessions take the form of a Scientist-to-Scientist interview in which a renowned speaker replies to questions from a colleague.

	Lessons from emergence of Coronaviruses over two decades
David Heymann United Kingdom	23 September 2020 - 10:15 – 10:45 CEST
	Interviewer: Jacob Moran-Gilad, Israel
	Zero risk doesn't exist but low risk does
Mark Roe Ireland	23 September 2020 - 16:30 – 17:00 CEST
	Interviewer: David Fisman, Canada
Benedetta Allegranzi	Clearing the clouds: recommendation on how to use PPE in the different phases of the SARS-CoV-2 pandemic
Switzerland	24 September 2020 - 10:45 – 11:15 CEST
	Interviewer: TBD
	Solving pandemic enigmas and communicating risk to the public
David Fisman Canada	25 September 2020 - 17:15 – 18:15 CEST
	Interviewer: Joel Mossong, Luxembourg



One-hour Symposia

One-hour symposia last 60 minutes and include 3 talks of 20 minutes each; two session chairs collect questions from the audience and facilitate discussion.

Session title: Children and schools during the COVID-19 pandemic: do school closures help?

Co-organised with the European Centre for Disease Prevention and Control

23 September 2020 - 09:00 - 10:00 CEST

Chairs	TBD		TBD
	Jonathan Suk Sweden	What does the evidence show on children's role in transmission?	
Speakers	Chiara Reno Italy	COVID-19 and the re-opening of schools: a policy maker's dilemma	
	Frode Forland Norway	Country perspective on policy making regarding school closures and opening	

Session title: COVID-19 and the lung

Co-organised with the European Respiratory Society (ERS)

23 September 2020 - 09:00 - 10:00 CEST

Chairs	Cristina Calarasu Romania		TBD
	Refika Hamutcu Ersu Canada	Paediatric respirology experience during the COVID-19 pandemic The TERAVOLT consortium: impact of SARS-CoV-2 on lung cancer Residual fibrotic lung disease in post-COVID-19 patients: pure imagination or solid reality?	
Speakers	Jan van Meerbeeck Belgium		
	Katerina Antoniou Greece		



One-hour Symposia

Session title: COVID-19 in immunosuppressed patients

Co-organised with the International Immunocompromised Host Society (ICHS), the Swiss Society for Infectious Diseases (SSID) and the ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

23 September 2020 - 09:00 - 10:00 CEST

Chairs	Oriol Manuel Switzerland		Monica Slavin Australia
ſS	David van Duin USA	Managing COVID-19 risks in immunocompromised Haematopoietic stem cell transplant and COVID-19 Solid organ transplant and COVID-19	
Speakers	Malgorzata Mikulska Italy		
	TBD		

Session title: COVID-19 in ICU: light and shadows

Co-organised with the ESCMID Study Group for Infections in Critically III Patients (ESGCIP), Croatian Society for Infectious Diseases of the Croatian Medical Assembly and the Croatian Society of Clinical Microbiology of the Croatian Medical Assembly

Chairs	Benoit Guery Switzerland		Garyphalia Poulakou Greece
	Marko Kutleša Croatia	Searching	for the optimal ICU treatment in COVID-19
Speakers	Matteo Bassetti Italy	Choosing ar	ntiviral treatment for SARS-CoV-2 pneumonia
	Patricia Muñoz Spain	COVID-related aspergillosis	



One-hour Symposia

Session title: Managing patients in the absence of evidence

Co-organised with the Trainee Association of ESCMID (TAE)

23 September 2020 - 11:30 - 12:30 CEST

Chairs	Bojana Beovic Slovenia		TBD
	Bjorn Hofmann Norway		eparating science from fiction: gnise low-quality and misleading research
Speakers	Juan Berenguer Spain	Making clinical decisions in the absence of evidence The Journal Editor's perspective: publishing in burning situ	
	Leonard Leibovici Israel		

Session title: Impact of COVID-19 on the elderly population

Co-organised with the ESCMID Study Group for Infections in the Elderly (ESGIE)

23 September 2020 - 17:15 - 18:15 CEST

Chairs	Dafna Yahav Israel		TBD
	Alison Roxby USA	Epidemiology of (COVID-19 in older adults in congregate settings
Speakers	Virginie Prendki Switzerland	Treatment of COVID-19 in the elderly	
S	Gaetan Gavazzi France	Ethical issues and ageism during COVID-19: should we deny hospitalisation or ICU admission to elderly?	



One-hour Symposia

Session title: COVID-19 immunophenotyping

23 September 2020 - 17:15 - 18:15 CEST

Chairs	TBD		Hanna Nohynek Finland
	Bali Pulendran A systems b		iology approach to determine host immune
	USA		responses to COVID-19
sus	Michael R. Betts		Mapping of immune perturbations
Speakers	USA	associated with severe COVID-19	
S	Eui-Cheol Shin	Immunophenotyping of COVID-19 and influenza	
	Korea	IIIIIIan	sphenotyping of COVID-19 and Initializa

Session title: Challenges to pathology in the COVID-19 era

Co-organised with the European Society of Pathology (ESP)

23 September 2020 - 17:15 - 18:15 CEST

Chairs	TBD		Amparo Fernandez Rodriguez Spain
	Cristina Basso Italy	Tissue and organ pathology of COVID-19 Detection of SARS-CoV-2 in bodily tissues Management of COVID-19 dead bodies, tissues and human remains	
Speakers	Paul Hofman France		
	TBD		



One-hour Symposia

Session title: What has genomics taught us about the epidemiology of SARS-CoV-2?

Co-organised with the American Society for Microbiology (ASM) and the ESCMID Study Groups for Epidemiological Markers (ESGEM) and for Staphylococci and Staphylococcal Diseases (ESGS) and for Genomic and Molecular Diagnostics (ESGMD)

23 September 2020 - 17:15 - 18:15 CEST

Chairs	Jennifer Gardy USA		Caroline Colijn Canada
	Nicholas Loman United Kingdom	Large-scale virus sequencing in the UK to support public health policy	
Speakers	Bas Oude Munnink Netherlands	Real-time SARS-C	CoV-2 sequencing to inform public health action
	Laurence Josset France	Identification of specific deletions in SARS-CoV-2 gene through sentinel surveillance	

Session title: Diagnostic pitfalls in COVID-19

Chairs	TBD		TBD
	Jim Huggett United Kingdom	Analytical perforr	nance and limitations of SARS-CoV-2 molecular detection
Speakers	Dana Wolf Israel	Sample poolin	g for SARS-CoV-2 detection: when and how?
S	Corine Geurts van Kessel Netherlands	IgG, IgM and IgA: what are the pertinent antibodies to detect COVID-19 diagnostics?	



One-hour Symposia

Session title: COVID-19: the first Digital Pandemic

Co-organised with Deutsche Gesellschaft für Infektiologie (DGI)

24 September 2020 - 09:00 - 10:00 CEST

Chairs	France Mentre France		Janne Vehreschild Germany
	James Watson Thailand	Scientific publishing standards: lessons learned from the Surgisphere incident Chances and risks of social media for emerging pandemics Essential components for successful European collaboration and network building in the COVID-19 era	
Speakers	Marcel Salathé Switzerland		
S	Evelina Tacconelli Italy		

Session title: Laboratory findings and biomarkers in COVID-19

Co-organised with the ESCMID Study Groups for Respiratory viruses (ESGREV) and for Implant-Associated Infections (ESGIAI)

Chairs	Barbara Rath Germany		Sotirios Tsiodras Greece
	Chrysanthi Skevaki Germany	Laboratory cha	racteristics of patients infected with SARS-CoV-2
Speakers	Zsuzsanna Varga Switzerland	Association of pathology findings with laboratory mar in COVID-19 illness	
	David Smadja France	Highly p	predictive novel biomarkers for severe COVID-19 illness



One-hour Symposia

Session title: National perspectives on contact tracing approaches for COVID-19

24 September 2020 - 11:30 - 12:30 CEST

Chairs	Joel Mossong Luxembourg		Annelies Verbon Netherlands
	Vernon Lee Singapore	Contact tracing with traditional and novel methods: the Singapore experience Contact tracing with traditional and novel methods: The South Korea experience Contact tracing with traditional and novel methods: The Hong Kong exprience	
Speakers	Dong-woo Lee South Korea		
	Ben Cowling China		

Session title: Global development of COVID-19 therapeutics

Co-organised with the Society of Infectious Diseases Pharmacists (SIDP)

24 September 2020 - 16:00 - 17:00 CEST

Chairs	Mark Gilchrist United Kingdom		TBD
	Hwa Lin Law Singapore	The Asian Experience The European Experience	
Speakers	Isabel Spriet Belgium		
	Zahra Escobar USA		The North American Experience



One-hour Symposia

Session title: Antimicrobial resistance and COVID-19: learning policy lessons from one another

Co-organised with the GAP-ON€ NETWORK

24 September 2020 - 17:15 - 18:15 CEST

Chairs	Till Bachmann United Kingdom		Sabiha Essack South Africa
			ne Health global issues: over-reaction to COVID-19 or under-reaction to AMR?
Speakers	Chantal Morel Switzerland	Will the	e COVID-19 pandemic impact costs of AMR? Adapting the GAP-ON€ framework
	Kevin Outterson USA	Devel	oping new treatments for new pathogens: lessons from AMR and COVID-19

Session title: SARS-CoV-2 epitopes

24 September 2020 - 17:15 - 18:15 CEST

Chairs	TBD		TBD
S	Pamela J. Bjorkman USA	Binding sites for neutralising antibodies Antibodies from COVID-19 patients define multiple targets of vulnerability	
Speakers	Marit J. van Gils Netherlands		
	TBD	Ν	Iultiple epitopes on SARS-CoV-2 spike



One-hour Symposia

Session title: SARS-CoV-2 zoonosis or reverse zoonosis?

Co-organised with ESCMID Study Group for Veterinary Microbiology (ESGVM)

24 September 2020 - 18:30 - 19:30 CEST

Chairs	Els Broens Netherlands		TBD
	Dong-Yan Jin Hong Kong	Zoonotic origins of human Coronaviruses	
Speakers	Gary R. Whittaker USA		COVID-19 and companion animals
	Arjan Stegeman Netherlands	Transmission of SARS-CoV-2 between humans and	

Session title: How to keep healthcare workers safe: preventing nosocomial spread

Co-organised with the ESCMID Study Group for Nosocomial Infections (ESGNI)

Chairs	Margreet Vos Netherlands		Evelina Tacconelli Italy
	Lydia Bourouiba USA	The theory of transmission of SARS-CoV-2: do aerosols significant role?	
Speakers	Mark Loeb Canada		otective Equipment and isolation rooms: what is edded in view of transmission routes?
	Elisabeth Presterl Austria	Showing tran	smissibility and deciding on infectiousness: do we need tests or just count the days?



One-hour Symposia

Session title: Co-infection with atypical pathogens in COVID-19 patients

Co-organised with the ESCMID Study Groups for Mycoplasma and Chlamydia Infections (ESGMAC) and for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

24 September 2020 - 18:30 - 19:30 CEST

Chairs	Ran Nir-Paz Israel		Kathrine Loens Belgium	
	Gilbert Greub Switzerland	The quest for additional pathogens in COVID-19 patients		
Speakers	Vicki Chalker United Kingdom	COVID-19 co-infection with atypical pathogens: geography matters		
	Maddalena Giannella Italy		Co-infection at hospital admission	

Session title: COVID-19 International clinical trials

Chairs	Jesus Rodrigue Spain	Bano	Robert Skov Denmark
	Florence Ader France		DISCOVERY Trial
Speakers	Srinivas Murthy Canada Soumya Swaminathan Switzerland	SOLIDARITY Trial	
	Peter Horby United Kingdom		RECOVERY Trial



One-hour Symposia

Session title: Corticosteroids in the management of COVID-19

Co-organised with the European Sepsis Alliance

25 September 2020 - 10:15 - 11:15 CEST

Chairs	TBD		TBD
S	Evangelos J. Giamarellos-Bourboulis Greece	S Complex immune dysregulation in severe COVID-19 Deregulated immune response to SARS-CoV-2: evidence-based use of corticosteroids Practical considerations for the use of corticosteroids in COVID- patients	
Speakers	Djillali Annane France		
	Garyphalia Poulakou Greece		

Session title: COVID-19: a reflection of healthcare and social inequity

Co-organised with the ESCMID Parity Commision

Chairs	Nur Benzonana Turkey		Onya Opota Switzerland	
	Manon Vouga Switzerland	COVID-19: risks and challenges during pregnancy		
Speakers	Axelle Ronsee Belgium	Managing COVID-19 patients in limited resources settings, including refugee camps		
	Pascal Lamy France	Dying from COVID19 or poverty: the dilemma between econo and health		



One-hour Symposia

Session title: The complex interaction of the human microbiota with SARS-CoV-2

Co-organised with the ESCMID Study Group for host and microbiota interaction (ESGHAMI)

25 September 2020 - 11:30 - 12:30 CEST

Chairs	Ed Kuijper Netherlands		Maria Vehreschild Germany	
	Ju-Sheng Zheng China	Gut microbiota may underlie the predisposition of individuals to COVID-19		
Speakers	Flavio De Maio Italy	Understanding the role of commensal members of the oropharyngeal microbiome on immunity and defense against COVID-19		
	Juliana De Castilhos Brasil	Oropharyngeal	microbiome signatures associated with the severity of COVID-19	

Session title: Digital Destiny: emerging disease platforms and epidemic risk assessments in the time of COVID-19

Co-organised with International Society for Infectious Diseases (ISID)

25 September 2020 - 16:00 - 17:00 CEST

Chairs	TBD		TBD
	Larry Madoff USA	ProMED: human data curation and finding COVID-19 on December 30, 2019 Global disease outbreaks: the view from 36,000 km	
Speakers	Assaf Anyamba USA		
	Sangeeta Bhatia United Kingdom	•	Il surveillance tools for near real-time mapping of international infectious disease spread



One-hour Symposia

Session title: COVID-19: epidemiology and impact of co-morbidities in Low and Middle Income Countries (LMICs)

Co-organised with the ESCMID International Affairs Subcommittee (EIAS)

25 September 2020 - 17:15 - 18:15 CEST

Chairs	Nicola Petrosillo Italy		Anja Šterbenc Slovenia
	Adrian J. Brink South Africa	The African COVID-19 pandemic In the middle of the storm: India and neighbouring countries South America: the new centre of the pandemic	
Speakers	Camilla Rodrigues India		
	Maria V. Villegas Colombia		

Session title: Vaccination mediated by expression of SARS-CoV-2 proteins in the host

25 September 2020 - 17:15 - 18:15 CEST

Chairs	Sotirios Tsiodras Greece		TBD
	TBD	A thermostable mRNA vaccine against COVID-19	
Speakers	Barney S. Graham USA	An mRl	NA vaccine expressing the prefusion-stabilised SARS-CoV-2 spike trimer
S	Dan H. Barouch USA	An Ad26 vector-based vaccine for SARS-CoV-2	



One-hour Symposia

Session title: Controversies surrounding antiparasitic drugs for COVID-19

Co-organised with the Lithuanian Society for Infectious Diseases and the ESCMID Study Group for Clinical Parasitology (ESGCP)

25 September 2020 - 18:30 - 19:30 CEST

Chairs	TBD		George Akpede Nigeria
	Nathan Peiffer-Smadja France	Hydroxychloroquine against SARS-CoV-2: pros and cons	
Speakers	Zeno Bisoffi Italy	Ivermectin against SARS-CoV-2: pros and cons Mitigating arrhythmia risk in hydroxychloroquine and azithromycin treated COVID-19 patients	
S	Kazimieras Maneikis Lithuania		

Session title: Wastewater and COVID-19: a tool for SARS-CoV-2 dynamic surveillance

Co-organised with the French Society of Microbiology (SFM) and the ESCMID Study Group for Food- and Water-borne Infections (EFWISG)

Chairs	Ana Freitas Portugal		Christophe Dagot France
S	Ana M. De Roda Husman Netherlands	Why survey viruses in wastewaters? Experience of the Netherlands with SARS-CoV-2 Risk assessment of wastewater in COVID-19 times Detection of SARS-CoV-2 in wastewater, a prediction tool?	
Speakers	Aaron Packman USA		
	Laurent Moulin France		



One-hour Symposia

Session title: The liver in SARS-CoV-2 infection

Co-orgnaised with the European Association for the Study of the Liver (EASL) and the ESCMID Study Group for Viral Hepatitis (ESGVH)

25 September 2020 - 18:30 - 19:30 CEST

Chairs	TBD		Moradpour Darius Switzerland
S	Ulrike Protzer Germany	The liver as target organ of SARS-CoV-2	
Speakers	TBD	Liv	er transplantation in the COVID-19 era
Š	Luca Valenti Italy	•	function, fatty liver and advanced liver fibrosis: rstanding the link to severe COVID-19

Session title: Innovative trials to optimise prevention and treatment of COVID-19

Co-organised with the European Clinical Research Alliance on Infectious Diseases

Chairs	TBD		Angela Hüttner Switzerland
	Henri van Werkhoven Netherlands	BCG vaccination of healthcare workers: a live IPD meta-analysis of ongoing trials	
Speakers	Chris Butler United Kingdom	The PRINCIPLE s	tudy: an adapative platform trial in primary care
	Lennie Derde Netherlands	an adapat	REMAP-CAP/COVID: ive platform trial in hospitalised patients



One-hour Symposia

Session title: Second wave of the COVID-19 pandemic: how to prepare?

Chairs	TBD	Shelly Bolotin Canada
s	Carolina Garcia Vidal Spain	The Spanish experience
Speakers	TBD	TBD
Ś	Colm Bergin Ireland	The Irish experience



One-hour Q&A

Q&A sessions last 60 minutes and include 2 talks of 20 minutes each, followed by 20 minutes of discussion; two session chairs will collect questions from the audience and facilitate discussion.

Session title: Influenza-SARS-CoV-2 co-circulation: lessons from the Southern hemisphere

23 September 2020 - 09:00 - 10:00 CEST

Chairs	TBD	Eeva Broberg Sweden
kers	Sheena Sullivan Australia	The Australian experience
Speakers	Cheryl Cohen South Africa	The South African experience

Session title: Acceleration of drug development and repurposing during the COVID-19 pandemic: a once in a lifetime chance?

Co-organised with the ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

Chairs	Markus Zeitlinger Austria		Francoise van Bambeke Belgium
ıkers	Marco Cavalleri Netherlands	Role of PK/PD and clinical evidence for accelerated drug development in a global pandemic: a regulatory perspective Pitfalls of PK/PD of repurposed drugs	
Speakers	Jeremy Guedj France		



One-hour Q&A

Session title: Tuberculosis and COVID-19: impact on TB programmes and clinical management

Co-organised with ESCMID Study Group for Mycobacterial Infections (ESGMYC)

23 September 2020 - 11:30 - 12:30 CEST

Chairs	Gustavo Velasquez USA		Florence Ader France
Speakers	Giovanni B. Migliori Italy	Impact of COVID-19 on TB services worldwide Managing COVID-19 in patients with DS- and DR-TB: when and how to treat	
Spea	Vivian Cox South Africa		

Session title: Masks in the public domain: pros and cons

Co-organised with the ESCMID Education Subcomittee

23 September 2020 - 17:15 - 18:15 CEST

Chairs	Muge Cevik United Kingdom		Gabriel Birgand France
kers	Erica Shenoy USA	Masks in the public domain: pros?	
Speakers	Andreas Voss Netherlands	ſ	Masks in the public domain: cons?



One-hour Q&A

Session title: HIV and COVID-19: what have we learned?

Co-organised by the European AIDS Clinical Society (EACS)

23 September 2020 - 18:30 - 19:30 CEST

Chairs	Ann Sullivan United Kingdom		Antonella D'Arminio Italy
Speakers	José Luis Blanco Spain	HIV and COVID-19 co-infection: what do we need to expect? The impact of COVID-19 on HIV prevention and STIs	
Spea	Gary Whitlock United Kingdom		

Session title: Paediatric COVID-19 infection in Europe

Co-organised with the European Society of Paedriatic Infectious Diseases (ESPID)

Chairs	Delane Shingadia United Kingdom		Oana Falup-Pecurariu Romania
kers	Begona Santiago Canada	Epidemiology of COVID-19 in Europe from the pTBnet survey Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS)	
Speakers	Liz Whittaker Ireland		



One-hour Q&A

Session title: The role of surfaces in COVID-19 disease

Co-organised with the ESCMID Study Group on Biofilms (ESGB)

23 September 2020 - 18:30 - 19:30 CEST

Chairs	Maria Dolores Macia Romero Spain		Elisa Borghi Italy
Speakers	Vincent J. Munster USA	Virus survival in air and surfaces	
Spea	Tom Coenye Belgium	Biofilm forr	nation on the surface of endotracheal tubes in COVID-19 patients

Session title: COVID-19 impact on migration

Co-organised with the ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

Chairs	Micaela Serafini Switzerland		TBD
kers	Sally Hargreaves United Kingdom	Migration, ethnicity and COVID-19 COVID-19 public health response and migrants' reception centres	
Speakers	Apostolos Veizis Greece		



One-hour Q&A

Session title: COVID-19 vaccines: what are the best candidates? How will they be accepted?

Co-organised with the ESCMID Vaccine Study Group (EVASG)

24 September 2020 - 11:30 - 12:30 CEST

Chairs	Antonietta Filia Italy		Ali Salanti Denmark
ıkers	Jean-Daniel Lelievre France	COVID-19 vaccine: unprecedented need, unprecedented efforts Vaccine hesitancy in the time of COVID-19	
Speakers	Pauline Paterson United Kingdom		

Session title: COVID-19 in the extremes of age

24 September 2020 - 17:15 - 18:15 CEST

Chairs	TBD		Aleksandra Barac USA
Speakers	Amy Greer Canada	COVID-19 in children: implications for schooling system	
Spea	Sean Kennelly Ireland	C	COVID-19 and long-term care facilities

Session title: Post-COVID-19 care

24 September 2020 - 17:15 - 18:15 CEST

Chairs	Marc Bonten Netherlands		Liz Whittaker United Kingdom
Speakers	Philip Zachariah USA	Post-COVID-19 in the young population Post-COVID-19 in the elderly	
Spea	Angelo Carfi Italy		



One-hour Q&A

Session title: COVID-19 pathophysiology and target-organ damage

Co-organised with the ESCMID Study Group for Infectious Diseases of the Brain (ESGIB) and for Forensic and Postmortem Microbiology (ESGFOR)

24 September 2020 - 18:30 - 19:30 CEST

Chairs	Veroniek Saegeman Belgium		Alexandra Mailles France
kers	Matthijs Brouwer Netherlands	Encephalitis, encephalopathy and vascular disorders Physiopathology associated with COVID-19 fatal outcome	
Speakers	Laurent Andreoletti France		

Session title: Healthcare building design to hold the next pandemic at bay

Co-organiser with the Irish Society of Clinical Microbiology and the European Committee on Infection Control (EUCIC)

25 September 2020 - **1**3:00 - 14:00 CEST

Chairs	TBD		Elisabeth Presterl Austria
ıkers	Lidia Morawska Australia	How COVID-19 will impact future healthcare setting design? Aerosol-generating procedures associated with SARS-CoV-2 transmission	
Speakers	Tara Palmore USA		



One-hour Q&A

Session title: Evidence-based medicine: another victim of COVID-19? What went wrong and what can we learn from it?

Co-organised with the ESCMID Guidelines Subcommittee

25 September 2020 - 17:15 - 18:15 CEST

Chairs	John McConnell United Kingdom		Luigia Scudeller Italy
kers	Andre Kalil USA	COVID-19 and evidence-based medicine: a tragedy with happy end? "By seeking and blundering we learn". How to create favourab conditions for evidence-based guidance in emergency situation	
Speakers	Benedikt Huttner Switzerland		

Session title: Science and communication during the COVID-19 pandemic

Co-organised with the Trainee Association of ESCMID (TAE)

Chairs	Marc Bonten Netherlands		Sylvia Briand France
kers	Helen Branswell USA	View from a journalist of the COVID-19 pandemic Do's and don'ts: the role of infectious diseases physicians/scientists in communicating science	
Speakers	Muge Cevik United Kingdom		



Meet the Expert

Meet-the-Expert sessions last 60 minute and feature two experts who give practical insight, exchange personal views and stimulate discussion with the audience.

Session title: How to detect SARS-CoV-2 infection?

Co-organised with the European Society for Clinical Virology (ESCV)

24 September 2020 - 09:00 - 10:00 CEST

Speakers	
Kate Templeton	Annemiek Vandereijk
United Kingdom	Netherlands

Session title: Changing paradigms on preparedness and response

25 September 2020 - 09:00 - 10:00 CEST

Speakers	
Paul Tambyah	Hélène Coignard-Biehler
Singapore	France

Session title: How do I manage COVID-19 pneumonia in ICU? From the early phase to late complications

Co-organised with the ESCMID Study Group for Infections in Critically III Patients (ESGCIP)

25 September 2020 - 09:00 - 10:00 CEST

Speakers	
Jean-François Timsit Antoni Torres	
France	Spain



Meet the Expert

Session title: How to generate evidence for pandemic response

25 September 2020 - 09:00 - 10:00 CEST

Speakers		
Christian Torp-Pedersen Ines Steffens		
Denmark	Sweden	

Session title: Dealing with super-infections in COVID-19 patients

Co-organised with the ESCMID Study Groups for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES) and Biofilm (ESGB)

25 September 2020 - 11:30 - 12:30 CEST

Speakers		
Alison Holmes Fernando Bozza		
UK	Brazil	

Session title: Translational research on COVID-19 immune response

Co-organised with the Italian Society of Microbiology (SIM)

Speakers		
Mauro Pistello Julian Pardo		
Italy	Spain	



23 – 25 September 2020 INVITED SPEAKER SESSIONS

Emerging threats, emerging solutions

Interview Sessions

ECCVID

Oral sessions are created from submitted abstracts; these are live sessions that last 60 minutes and include 5 presentations (10 minutes), each followed by 2 minutes Q&A.

Abstract Sessions

Session title: Performance of COVID-19 serology

23 September 2020 - 09:00 - 10:00 CEST

Chairs	TBD		Vitali Sintchenko Australia
	Larent Dortet France	Evaluating ten commercially available SARS-CoV-2 rapid serological tests using the STARD (Standards for Reporting of Diagnostic Accuracy Studies) method	
S	TIEIKE WEISSET		dried blood spots as alternative sampling material al detection of anti-SARS-CoV-2 antibodies using established ELISAs
Speakers	Hanssen Daniëlle Netherlands	Evaluation of 16 commercial serological assays for the of antibodies against SARS-CoV-2 in paired serum sa	
	Ram Dessau Denmark	Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen Danish clinical laboratories	
	Dennis Souverein Netherlands	Association between patient-reported symptoms and SARS-Cov serological test results	

ECCVID

Session title: Controlling transmission in healthcare facilities

23 September 2020 - 10:15 - 11:15 CEST

ch air	TBD		TBD
	Vera Schwierzeck Germany	Transmission dynamics of healthcare-associated SARS-CoV-2 in a German university hospital	
	Alexander Hesselberg Løvestad Norway	Outbreak investigation of SARS-CoV-2 among hospital healthca workers using nanopore whole-genome sequencing Containment of COVID-19 in a complex multi-institutional healthcare system over a six-month period: the role of patier segregation, risk-stratified testing, centralised surveillance an universal masking	
Speakers	Sng Edwin Singapore		
	Irena Grmek Košnik Slovenia	"Ad hoc" app	roach to control COVID-19 outbreaks in long-term care facilities (LTCF)
	Karen Nadua Singapore	Evaluating the risk of COVID-19 infection in discordant care child dyads admitted to a paediatric hospital	



Abstract Sessions

Session title: Improving molecular SARS-CoV-2 detection

23 September 2020 - 10:15 - 11:15 CEST

Chairs	TBD		Jaroslav Hrabak Czech Republic	
		of efficiency and sensitivity of 1D and 2D sample strategies for diagnostic screening purposes		
	Opota Onya Switzerland	Computer-aided medical microbiology monitoring tool: a strategy to adapt to the SARS-CoV-2 epidemic and that highlights RT-qPCR consistency		
Speakers	Jansen Ruud Netherlands	Introducing the direct lysis method for fast and reliable SARS-CoV 2 detection by PCR without DNA/RNA extraction		
	Nicolo Musso Italy	Droplet digital PCR as the best sensitive assay for the SARS-CoV-2 detection		
	Sundqvist Martin Sweden	Gurgled pharyngeal sample as alternative to nasopharyngeal swabs for the detection of SARS-CoV-2 RNA		



Abstract Sessions

Session title: Broader societal impact of the pandemic

23 September 2020 - 16:00 - 17:00 CEST

Chairs	Sotirios Tsiodras Greece		Jonathan Suk Sweden	
Speakers	Carlos Crespo Spain	Economic impact of COVID-19 pandemic across Europe		
	Juliane Vismari de Oliveira Brazil	COVID-19 and São Paulo slums: social vulnerability as a catalyst for deaths		
	Dambula Felix Mojo Malawi	COVID-19 and social inequalities		
	Joana Valente Dias Portugal	The impact of social isolation on the well-being of children during SARS-CoV-2 pandemic		
	Ciara Conlan Ireland	admitted w	richer or for poorer: level of deprivation in patients ith COVID-19 compared to the usual respiratory admission cohort in a Dublin Hospital	



Abstract Sessions

Session title: Surveillance studies in different settings

23 September 2020 - 16:00 - 17:00 CEST

Chairs	Richard Goering USA		Natacha Couto United Kingdom	
Speakers	Wong Tzu-Jung Singapore	A symptom-based patient surveillance system at the ward level: a pilot project in a public tertiary hospital in Singapore		
	Margarita Poza Spain	Highly predictive regression model of active cases of COVID-19 in a population by screening wastewater viral load		
	Rahel Stadler Switzerland	Systematic screening on admission for SARS-CoV-2 to detect asymptomatic infections		
	Jamil Kanji Canada	Retrospective COVID-19 testing of respiratory specimens to evaluate for earlier circulation of SARS-CoV-2 in Alberta, Canada		
	Mircea Sofonea France		ical monitoring and comparative analysis of non- ical interventions using a parsimonious modelling framework	



Abstract Sessions

Session title: Bioinformatics and genomic applications

23 September 2020 - 18:30 - 19:30 CEST

Chairs	TBD		Nuno Faria United Kingdom	
	Ivan Topolsky Switzerland	Applying V-pipe to SARS-CoV-2 data		
	Varona Sarai Spain	nf-core/viralrecon: a bioinformatics pipeline for SARS-CoV-2 genome analysis, from quality control to consensus genome sequence		
Speakers	Mari Alfredo Switzerland	COVID-19 Genome Analysis Pipeline (COVGAP): tracking antivitive resistance of SARS-CoV-2		
	Anton Korobeynikov Russia	CoronaSPAdes: from biosynthetic gene clusters to coronavira assemblies		
	Marcelo Soares Spain	SARS-CoV-2 genomic and quasispecies analyses in cancer patie reveal relaxed intra-host virus evolution		



Abstract Sessions

Session title: SARS-CoV-2 viral shedding and kinetics

r ir	TBD		TBD	
	Adriana Tami Netherlands	The COVID-HOME study: prospective cohort study of non- hospitalised COVID-19 patients. Part I: duration and routes of vira shedding, genetic diversity, and development of immunity		
S	Judith Berastegui- Cabrera Spain	SARS-CoV-2 RNAaemia in COVID-19 adult patients association to clinical findings and outcome		
Speakers	Flora Marzia Liotti Italy	SARS-CoV-2 RNA positivity in recovered COVID-19 patients is de to low levels of non-replicating virus		
	Maria Vittoria Mauro Italy	Persistence of SARS-CoV-2 in faeces and potential transmission		
	Joe Standing United Kingdom	Systematic review and patient-level meta-analysis of SARS-Co viral dynamics to model response to antiviral therapies		



Abstract Sessions

Session title: Genomic epidemiology informs pandemic control

Chairs	Adrian Egli Switzerland		TBD	
	William Hamilton United Kingdom	COVID-19 infection dynamics in care homes in the East of Engl a retrospective genomic epidemiology study		
Gonzalez-C Spai	Fernando Gonzalez-Candelas Spain	Genomic epidemiology of SARS-CoV-2 in Spain		
Speakers	Tamer Abdelrahman Luxembourg	Genomic mapping of SARS-CoV-2 using deep sequencing Luxembourg		
	Mary Lucey Ireland	-	me sequencing confirms nosocomial SARS-CoV-2 ion between healthcare workers and patients	
	Madlen Stange Switzerland	Phylogenetic analysis of the early phase of the SARS-CoV-2 pandemic in Basel		



Abstract Sessions

Session title: Public health policy aspects

	Chairs	Vicki Chalk o United Kingd		Fernando Gonzalez Candelas Spain	
		Nir-Paz Ran Israel	Moderate and severe COVID-19 cases: a sensitive indicator for effects of closures and re-openings		
		Jean-Philippe Rasigade France	SARS-CoV-2 phylodynamics differentiates the effectiveness o non-pharmaceutical interventions		
	Speakers	Claudia Recanatini Netherlands	Safer with patients: healthcare workers' vulnerability duri the COVID-19 pandemic		
	S	Laura O'Doherty Ireland	Effectiveness of the response to COVID-19 of homeless ser Dublin, Ireland		
		Jose Mauricio Hernandez Sarmiento Colombia	Engaging with indigenous communities during COVID-19 pandemic: the case of Tribugá- Choco region in Colombia		



Abstract Sessions

Session title: Host response and immunomodulation

Chairs	Roy Chema USA	νy	Evangelos J. Giamarellos-Bourboulis Greece		
	Tim Sweeney USA	Comparison of a host response classifier to IL-6 and other clinical markers for predicting severe respiratory failure in COVID-19			
	Rory de Vries Netherlands	Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome			
Speakers	Nico Janssen United Kingdom	A systems-based approach of inflammatory biomarkers discriminates between severe and critical COVID-19			
	Aline de Nooijer Netherlands	Complement activation in the disease course of COVID-19 and effects on clinical outcomes			
	Marco Franzetti Italy	Interleukin-1 receptor antagonist Anakirna in the treatment o COVID-19 ARDS: an observational study			



Abstract Sessions

Session title: Tools for predicting COVID-19 outcome

	Chairs	Daniele Roberto Giacobbe Italy		Carolina Vidal Spain		
		Jesús Rodríguez-Baño Spain	Development and validation of phenotypes for COVID-19 patie with prognostic implications (FEN-COVID project)			
		Hélder Pinheiro Portugal		impact in the SARS-CoV-2 infection outcomes: the lue of microbial fingerprinting for disease severity		
eakers	Speakers	Liam Townsend Ireland	A machine learning approach identifies a key role for neutropl maturity in severe COVID-19 infection and generates a predicti model			
	S	Fredrikke Christie Knudtzen Denmark		2 viral load as a predictor for disease severity in its and hospitalised patients with COVID-19: a prospective cohort study		
		Maria Madeleine Rüthrich Germany	COVID-19 in cancer patients: clinical characteristics and outcom An analysis of the LEOSS registry			



Abstract Sessions

Session title: News on SARS-CoV-2 pathophysiology, diagnosis and treatment

25 September 2020 - 14:45 - 15:45 CEST

Chairs	Hege Aamot Norway		TBD		
	Vivek Thacker Switzerland	Rapid endothelial infection, endothelialitis and vascular dama characterise SARS-CoV-2 infection in a human lung-on-chip mo			
	TBD	Autopsy report of 7 deceased COVID-19 patients			
Speakers	Kenneth Rand USA	Discordant SARS-CoV-2 RT-PCR nasopharyngeal swab tests may result from biological variability in nasopharyngeal viral distribution			
Spea	Ilad Alavi Darazam Iran	Umi	fenovir in hospitalised COVID-19 patients		
	Balint Gergely Szabo Hungary	Role of favipiravir in the treatment of adult patients wit to severe COVID-19: a single-center, prospective, ob sequential cohort study from Hungary			



Abstract Sessions

Session title: Local COVID-19 epidemiology across different regions

25 September 2020 - 14:45 - 15:45 CEST

	ch air	TBD		TBD		
		Oscar Diaz Honduras	Impact of a multi-mechanism approach on COVID-19 case fatali rate: the experience of a developing country			
		Syed Faisal Mahmood Pakistan	Local epidemiology and outcomes of COVID-19 in a Low-Middle Income Country			
	Speakers	Lisandra Serra Damasceno Brazil	Trend of COVID-19 in Latin America Characteristics of incidence rate of COVID-19, acute respirator diseases, influenza and community acquired pneumonia in Rus according to climate, geographical aspects and population dens			
		Natalia Pshenichnaya Russia				
		Direk Limmathurotsakul Thailand		between mask-wearing, handwashing and social actices and risk of COVID-19 infection in public: a case-control study in Thailand		



Abstract Sessions

Session title: Management of COVID-19 patients

Chairs	TBD		Guido Werner Germany		
	Kristen Marks USA	Baseline characteristics associated with clinical improvement and mortality in hospitalised patients with severe COVID-19 treated with remdesivir			
	Serena Vita Italy	Use of steroids in patients with COVID-19 pneumonia: is there an additional clinical benefit in terms of clinical outcome?			
Speakers	Rita Murri Italy	An artificial intelligence framework based on real-world data support clinical decision-making for COVID-19 patients			
	Claire Dupuis France	-	y corticosteroids on day 60 mortality in critically ill ith COVID-19: a multicenter cohort study of the OUTCOMEREA network		
	Yasmin Maor Israel	moderate a	ate use of convalescent plasma for treatment of and severe pneumonia in COVID-19 patients and on with IgG antibody levels in donated plasma		



Abstract Sessions

Session title: Testing policies in healthcare institutions

Chairs	Nasia Safdar USA		Annelies Verbon Netherlands	
	Marta Santos Bravo Spain	Subgenomic RNA as a surrogate marker for active SARS-CoV-2 replication in healthcare workers for work reincorporation		
	Astrid Füszl Austria	SARS-CoV-2 screening of persistently asymptomatic patients implies negativity for at least 3 days		
Speakers	Amoolya Vusirikara United Kingdom	Early mass testing after a single case of suspected or confirmed COVID-19 in care homes in London, U.K., April-May 2020: implications for policy and practice		
	Xiang Ying Jean Sim Singapore	Utilising the electronic health records to create a syndromic sta surveillance system during the COVID-19 outbreak		
	Susan Butler-Wu USA	Asymptomatic testing for SARS-CoV-2 in the hospital setting: is the juice worth the squeeze?		



Clinical Case Sessions

Session title: COVID-19 presentation

	Chairs	TBD		Lior Nesher Israel			
		Dorsaf Slama France	Coronavirus myopericarditis: viral or post-infections origin?				
			nal pain due to epiploic appendagitis: an overlooked nbotic complication of SARS-CoV-2 infection				
	Speakers	Zahit Tas Turkey	A case of Crimean-Congo haemorrhagic fever (CCHF) mimicking COVID-19				
		Ariane Vanderick Belgium	Pancytopaenia and myocarditis: an atypical presentation of COVID-19 infection				
		Flavia Cunha Portugal	COVID-19/Tuberculosis co-infection: the road to an unexpec diagnosis				



Clinical Case Sessions

Session title: COVID-19 treatment challenges

Chairs	Nina Khanr Switzerlan		TBD		
	Philippe Clevenbergh Belgium	A case report of serious haemolysis in a Glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine			
	Elpis Chochliourou Greece	A favourable outcome in a critically ill young child with COVID- and underlying disease			
Speakers	Sherika Ranasinghe United Kingdom	TB-COVID-19: double trouble			
	Pietro Vitale Italy	Acute pancreatitis in a COVID-19 patient treated with remeted to cilizumab and methylprednisolone			
	Alexandre Malek USA	COVID-19 pneumonia in the pre-engraftment period after haematopoietic cell transplantation (HCT): clinical and therap challenges			



Clinical Case Sessions

Session title: COVID-19 complications

	Chairs	Gustavo Lopa Argentina		Graeme Meintjes South Africa	
				ak of MDR <i>Klebsiella pneumoniae</i> infections and n a temporary ICU during the COVID-19 pandemic	
		TBD	Reversible myoclonus-ataxia as a post-infectious manifestation of COVID-19		
	Speakers	Oana Sandulescu Romania	Post-COVID-2	19 immune hepatitis in a young male with no pre- existing comorbidities	
Sp	S	Pei Hua Lee and David LyeAbdominal andSingapore		d right lower limb arterial thrombosis in a COVID-19 patient	
		Vanlede Koen Belgium	6 year old Belgian boy with MIS-C with Kawasaki-like feature		



Clinical Case Sessions

Session title: The course of COVID-19

Chairs	Cristiana Oprea Romania		Sarah Tschudin-Sutter Switzerland	
	Elham Khatamzas United Kingdom	Prolonged infe	nged infectious virus shedding in a severe case of COVID-19	
	Kamelia R. Stanoeva Netherlands	COVID-19 reinfection?		
Speakers	Kirsten Schaffer Ireland	Discordant RT-qPCR results in a COVID-19 patient challenges clinical decisions		
	Etienne Ruppé France	Monitorii	ng the microbiota in severe COVID-19 patients	
	Cláudio J. N. Nunes Portugal	Recurrence	of symptoms during COVID-19 convalescence: a diagnostic challenge	



Practical Workshops

Session title: Phylogenetic analysis and molecular epidemiology of SARS-CoV-2

23 September 2020 - 13:00 - 15:00 CEST

Coordinator: Richard Neher, Switzerland

	First Part			
	Richard Neher Switzerland	Introduction into phylogenetics and molecular epidemiology		
Instructors	Emma Hodcroft Switzerland	Overview of SARS-CoV-2 evolution in Nextstrain		
Ľ	Áine O'Toole United Kingdom	SARS-CoV-2 diversity, clades, and lineages		
	Second	Part		
Instructors	Emma Hodcroft and Richard Neher	Quality control, clade assignment, and phylogenetic placement with next clade		
Inst	Áine O'Toole	Lineage assignment using pangolin and llama		

Registered participants will have the opportunity to ask questions via chat. Please register following this link: <u>https://escmid-org.zoom.us/webinar/register/WN_z4PwuQMWS7-UZry-Rs-KSA</u>



Practical Workshops

Session title: Diagnostics: how to perform different PCR protocols to detect SARS-CoV-2

24 September 2020 - 13:00 - 15:00 CEST

Coordinator: Prof. Gilbert Greub, Switzerland

	Gilbert Greub Switzerland
Instructors	Onya Opota Switzerland
-	Claire Bertelli Switzerland

Registered participants will have the opportunity to ask questions via chat. Please register following this link: <u>https://escmid-org.zoom.us/webinar/register/WN_XMYPJJFxSjuSLGeFSYE-yw</u>

Session title: Diagnostics: how to perform serological tests to detect SARS-CoV-2 infection

25 September 2020 - 13:00 - 15:00 CEST

Coordinator: Gilbert Greub, Switzerland

	Gilbert Greub Switzerland	SARS-CoV-2 serological assays
nstructors	Craig Fenwick Switzerland	Neutralizing antibodies and neutralisation assays
드	Giuseppe Pantaleo Switzerland	Anti-SARS-CoV-2 vaccines

Registered participants will have the opportunity to ask questions via chat. Please register following this link: <u>https://escmid-org.zoom.us/webinar/register/WN_OebGntv6ToiThARpEX6oJw</u>



Practical Workshops

Session title: COVID-19 therapeutics

Time: TBD

Coordinator: José Ramón Pano-Pardo, Spain

	José R. Paño Spain	What makes prescribers prescribe (or not prescribe) when in pandemic mode?
nstructors	Jesús Rodríguez-Baño Spain	Trialist, observartionalist, plausibilist?
Instru	José R. Arribas Spain	Mild, moderate and severe COVID-19
	Bruno Megarbane France	Critically-ill COVID-19 patients

Registered participants will have the opportunity to ask questions via chat. Please register following this link: <u>https://escmid-org.zoom.us/webinar/register/WN_x6vFOYZ6RJWNPJo01LQQ2g</u>



VIL - Virtual Industry Learnings

Virtual Industry Learnings are organised by companies that wish to broadcast scientific and commercial content related to their main activities or that aim at addressing a topic from a specific point of view.

Illumina	Global response to COVID-19
mumma	23 September 2020 - 14:00 – 15:00 CEST
Seegene	Clinical validation and cases of using Seegene COVID-19 real-time PCR product
	23 September 2020 - 14:00 – 15:00 CEST
BD Diagnostics	Advancing COVID-19 diagnostic innovation across the testing pathway: a scientific expert panel discussion with live Q&A
	23 September 2020 - 14:15 – 15:45 CEST
Quidel	Managing scarcity: effective algorithms incorporating innovative technologies for administering COVID-19 diagnostic testing in the hospitals and community
	23 September 2020 - 14:30 – 15:30 CEST
Abbott	Testing Patients Suspected of COVID-19: Clinicians from New York and Rio de Janeiro Share Their Perspectives
	23 September 2020 - 15:00 – 16:00 CEST
Biomérieux	The role of diagnostic solutions for COVID-19 patients: diagnosis, prognosis, complications and follow-up
	24 September 2020 - 13:00 – 14:00 CEST
Thermo Fischer	Current challenges & learning to advance Antibiotic Stewardship in the wake of Coronavirus
Scientific	25 September 2020 - 14:45 – 14:45 CEST

ESCMID Conference on **Coronavirus** Disease



23 – 25 September 2020 **INDUSTRY SESSIONS**

VIS - Virtual Integrated Symposia

These sessions are proposed by companies based on specific criteria formulated by ESCMID and are evaluated by the ECCVID Programme Committee. ESCMID appoints an independent chair.

Session title: AstraZeneca - Targeting SARS-CoV-2: novel vaccines and antivirals for the prevention and treatment of COVID 19

Agenda	Chairs	ESCMID-appointed Chair TBD	Industry Chair TBD
09:00 - 09:05			airs luction
09:05 - 09:20	rs	Sarah Gilbert United Kingdom	New advances in COVID 19 vaccine development
09:20 - 09:35	Speakers	Mark Esser USA	How do you manage COVID-19 associated fungal infections in the middle of a national outbreak?
09:35 – 10:00	All Q&A		



VIS - Virtual Integrated Symposia

Session title: Seegene - Breakthrough of pandemic times: cases of different region and countries, multiplex test of SARS-CoV-2 and other respiratory viruses

23 September 2020 - 10:15 - 11:15 CEST

Chairs	ESCMID-appointed Chair Eric Claas Netherlands		Industry Chair Antonio M. Gonçalves Portugal
	Hyuk Min Lee South Korea	Early imple	ementation of diagnostic system for COVID-19 in South Korea
Speakers	Carlos Gouvêa Brazil	Invasive aspergillosis and COVID-19: uncovering the hidden threat	
	Anja Oštrbenk Valenčak Slovenia	Need for co-	testing of SARS-CoV-2 and essential respiratory viruses

Session title: *PFIZER* - COVID-19 secondary infections: understanding the threat of opportunistic bacteria and fungi

ESCMID-appointed Chair Industry Chair Chairs Agenda TBD **Philippe Montravers** France Chairs 16:00 - 16:05 Welcome and introduction Spotlight on the management of **Antoni Torres** 16:05 - 16:20 bacterial-SARS-CoV-2 Spain Speakers co-infections and superinfections **Robert Krause** Invasive aspergillosis and COVID-19: 16:20 - 16:35 Austria uncovering the hidden threat All 16:35 - 17:00 Panel discussion



VIS - Virtual Integrated Symposia

Session title: *MSD* - Secondary bacterial infections complicating COVID-19: how do they compare to those complicating influenza?

Agenda	Chairs	ESCMID-appointed Chair Bhanu Sinha Netherlands	Industry Chair Souha Kanj Lebanon
17:15 – 17:20		-	airs opening remarks
17:20 - 17:32		Ricard Ferrer Spain	Bacterial pneumonia complicating COVID 19 vs influenza: when and with what organisms?
17:32 - 17:44	Speakers	Alex Soriano Spain	Establishing the diagnosis of secondary bacterial pneumonia: implication on outcome
17:44 – 17:56	•	Susan Davis USA	Clinical management, guidelines and treatment approaches: driven by local ecology?
17:56 - 18:11		All Panel discussion and Q&A	
18:11 – 18:15		Chairs Closing remarks	



VIS - Virtual Integrated Symposia

Session title: GILEAD - Invasive fungal infections and COVID-19: expect the unexpected?

Agenda	Chairs	ESCMID-appointed Chair Oliver Cornely Germany	Industry Chair Michael von Bergwelt-Baildon Germany
17:15 – 17:20	Chairs Welcome and introduction		
17:20 - 17:35		Paul Verweij Netherlands	Estimating the burden of COVID-19- associated fungal disease, risk factors and diagnostic challenges
17:35 - 17:50	Speakers	Jim Buckley United Kingdom	How do you manage COVID-19 associated fungal infections in the middle of a national outbreak?
17:50 - 18:05	S	Dimitrios Kontoyiannis USA	The conundrums of COVID-19 in cancer patients: unique considerations of risk of severity and management
18:05 – 18:15	All Q&A		



VIS - Virtual Integrated Symposia

Session title: Beckman Coulter Life Sciences - Recognising the immune response to SARS-CoV-2 24 September 2020 - 17:15 – 18:15 CEST

Chairs	ESCMID-appointed Chair TBD		Industry Chair Tracy Andrews United Kingdom
ers	Andrea Cossarizza Italy	Recognising the immune response to SARS-CoV-2	
Speakers	Nikhil Gopalkrishnan and Josie Kishi USA		up testing at scale to enable COVID-19 decision makers

Session title: GILEAD - Bringing antiviral expertise to pandemic times

25 September 2020 - 18:30 - 19:30 CEST

Agenda	Chairs	ESCMID-appointed Chair	Industry Chair Andrew Ustianowski United Kingdom
18:30 – 18:40	Speakers	Andrew Ustianowski United Kingdom	Time to respond
18:40 – 18:55		Alex Soriano United Kingdom	Time to innovate
18:55 – 19:10		Raffaele Bruno Italy	Time to collaborate
19:10 - 19:30	All Time to discuss		